<unk>  is a vaccine, being developed by<unk> bis, which is intended to provide lifelong protection against all strains of Influenza A. The vaccine targets the M2 protein which is found on the surface of all strains of Influenza A.
The vaccine has been tested in a human trial, in the United States, where it is claimed to have successfully protected 90% of individuals against the<unk>  virus. Further human trials are planned.
ACAM-FLU-A
PAC-1
IC-26
Cadherin
DPI-3290
DPI-287
Integrin
Fibroblast growth factor receptor